Search

Your search keyword '"Prica, Anca"' showing total 551 results
Start Over Author "Prica, Anca"
551 results on '"Prica, Anca"'

8. Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Results of a pilot randomized trial RBC‐ENHANCE

Author

Buckstein, Rena, primary, Callum, Jeannie, additional, Prica, Anca, additional, Bowen, David, additional, Wells, Richard A., additional, Leber, Brian, additional, Heddle, Nancy, additional, Chodirker, Lisa, additional, Cheung, Matthew, additional, Mozessohn, Lee, additional, Yee, Karen, additional, Gallagher, Jennifer, additional, Parmentier, Anne, additional, Jamula, Erin, additional, Zhang, Liying, additional, Mamedov, Alex, additional, Stanworth, Simon J., additional, and Lin, Yulia, additional

Published
2024
Full Text
View/download PDF

12. A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia

Author

Cheung, Matthew C., Mittmann, Nicole, Owen, Carolyn, Abdel-Samad, Nizar, Fraser, Graeme A.M., Lam, Selay, Crump, Michael, Sperlich, Catherine, van der Jagt, Richard, Prica, Anca, Couban, Stephen, Woyach, Jennifer A., Ruppert, Amy S., Booth, Allison M., Mandrekar, Sumithra J., McDonald, Gail, Shepherd, Lois E., Yen, Hope, Chen, Bingshu E., and Hay, Annette E.

Published
2021
Full Text
View/download PDF

13. Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Combined results from two randomized controlled feasibility studies

Author

Buckstein, Rena, primary, Callum, Jeannie, additional, Prica, Anca, additional, Bowen, David, additional, Wells, Richard A., additional, Leber, Brian, additional, Heddle, Nancy, additional, Chodirker, Lisa, additional, Cheung, Matthew, additional, Mozessohn, Lee, additional, Yee, Karen, additional, Gallagher, Jennifer, additional, Parmentier, Anne, additional, Jamula, Erin, additional, McQuilten, Zoe, additional, Wood, Erica M., additional, Weinkov, Robert, additional, Zhang, Liying, additional, Mamedov, Alex, additional, Stanworth, Simon J., additional, and Lin, Yulia, additional

Published
2023
Full Text
View/download PDF

14. Hematopoietic Cell Transplantation Trends and Outcomes in Canada: A Registry-Based Cohort Study

Author

Seftel, Matthew D., primary, Pasic, Ivan, additional, Parmar, Gaganvir, additional, Bucher, Oliver, additional, Allan, David S., additional, Bhella, Sita, additional, Hay, Kevin Anthony, additional, Ikuomola, Oluwaseun, additional, Musto, Grace, additional, Prica, Anca, additional, Richardson, Erin, additional, Truong, Tony H., additional, and Paulson, Kristjan, additional

Published
2023
Full Text
View/download PDF

16. Indolent lymphoma care delivery and outcomes during the COVID‐19 pandemic in Ontario, Canada.

Author

Gong, Inna Y., Prica, Anca, Ante, Zharmaine, Calzavara, Andrew, Krzyzanowska, Monika K., Singh, Simron, Suleman, Adam, Cheung, Matthew C., and Crump, Michael

Subjects
*COVID-19, *COVID-19 pandemic, *EMERGENCY room visits, *PROPORTIONAL hazards models, *LYMPHOMAS, *FEBRILE neutropenia
Abstract

Summary: The treatment pattern and outcomes in patients with indolent B‐cell lymphoma treated during the coronavirus disease 2019 (COVID‐19) pandemic period compared to the prepandemic period are unclear. This was a retrospective population‐based study using administrative databases in Ontario, Canada (follow‐up to 31 March 2022). The primary outcome was treatment pattern; secondary outcomes were death, toxicities, healthcare utilization (emergency department [ED] visit, hospitalization) and SARS‐CoV‐2 outcomes. Adjusted hazard ratios (aHR) from Cox proportional hazards models were used to estimate associations. We identified 4143 patients (1079 pandemic, 3064 prepandemic), with a median age of 69 years. In both time periods, bendamustine (B) + rituximab (BR) was the most frequently prescribed regimen. During the pandemic, fewer patients received R maintenance or completed the full 2‐year course (aHR 0.81, 95% CI 0.71–0.92, p = 0.001). Patients treated during the pandemic had less healthcare utilization (ED visit aHR 0.77, 95% CI 0.68, 0.88, p < 0.0001; hospitalization aHR 0.81, 95% CI 0.70–0.94, p = 0.0067) and complications (infection aHR 0.69, 95% CI 0.57–0.82, p < 0.0001; febrile neutropenia aHR 0.66, 95% CI 0.47–0.94, p = 0.020), with no difference in death. Independent of vaccination, active rituximab use was associated with a higher risk of COVID‐19 complications. Despite similar front‐line regimen use, healthcare utilization and admissions for infection were less in the pandemic cohort. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Combined results from two randomized controlled feasibility studies.

Author

Buckstein, Rena, Callum, Jeannie, Prica, Anca, Bowen, David, Wells, Richard A., Leber, Brian, Heddle, Nancy, Chodirker, Lisa, Cheung, Matthew, Mozessohn, Lee, Yee, Karen, Gallagher, Jennifer, Parmentier, Anne, Jamula, Erin, McQuilten, Zoe, Wood, Erica M., Weinkov, Robert, Zhang, Liying, Mamedov, Alex, and Stanworth, Simon J.

Published
2024
Full Text
View/download PDF

21. Mortality among patients with diffuse large B-cell lymphoma and mental disorders: a population-based study

Author

Gong, Inna Y, primary, Cheung, Matthew C, additional, Chan, Kelvin K W, additional, Arya, Sumedha, additional, Faught, Neil, additional, Calzavara, Andrew, additional, Liu, Ning, additional, Odejide, Oreofe O, additional, Abel, Gregory, additional, Kurdyak, Paul, additional, Raphael, Michael J, additional, Kuczmarski, Thomas, additional, Prica, Anca, additional, and Mozessohn, Lee, additional

Published
2023
Full Text
View/download PDF

22. PB2358: PHASE 1-2 STUDY OF THE SAFETY, PK, PD, AND PRELIMINARY ACTIVITY OF TOLINAPANT IN COMBINATION WITH ORAL DECITABINE/CEDAZURIDINE AND ORAL DECITABINE/CEDAZURIDINE ALONE IN SUBJECTS WITH R/R PTCL

Author

Shortt, Jake, primary, Poligone, Brian, additional, Ribrag, Vincent, additional, Zinzani, Pier Luigi, additional, El-Sharkawi, Dima, additional, Walewski, Jan, additional, Prica, Anca, additional, Wilson, Laksmi, additional, Souza, Sonia, additional, Keer, Harold, additional, Taylor, Jason, additional, and Marchi, Enrica, additional

Published
2023
Full Text
View/download PDF

24. Ibrutinib Plus RCHOP versus RCHOP Only in Young Patients with Activated B-Cell-like Diffuse Large B-Cell Lymphoma (ABC-DLBCL): A Cost-Effectiveness Analysis.

Author

Rho, Hayeong, Jeong, Irene Joo-Hyun, and Prica, Anca

Subjects
DIFFUSE large B-cell lymphomas, QUALITY-adjusted life years, COST effectiveness, MARKOV processes
Abstract

The standard treatment for Diffuse Large B-Cell Lymphoma (DLBCL) is rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP). However, many patients require subsequent treatment after relapsed disease. The ABC subtype of DLBCL (ABC-DLBCL) has a worse prognosis, and the PHOENIX trial explored adding ibrutinib to RCHOP for this patient population. The trial showed favorable outcomes for younger patients, and our study aimed to inform clinical decision-making via a cost-effectiveness model to compare RCHOP with and without ibrutinib (I-RCHOP). A Markov decision analysis model was designed to compare the treatments for patients younger than 60 years with ABC-DLBCL. The model considered treatment pathways, adverse events, relapses, and death, incorporating data on salvage treatments and novel therapies. The results indicated that I-RCHOP was more cost-effective, with greater quality-adjusted life years (QALY, 15.48 years vs. 14.25 years) and an incremental cost-effectiveness ratio (ICER) of CAD 34,111.45/QALY compared to RCHOP only. Sensitivity analyses confirmed the model's robustness. Considering the high market price for ibrutinib, I-RCHOP may be more costly. However, it is suggested as the preferred cost-effective strategy for younger patients due to its benefits in adverse events, overall survival, and quality of life. The decision analytic model provided relevant and robust results to inform clinical decision-making. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

27. Suppl Fig 2 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Author

Chavez, Julio C., primary, Foss, Francine M., primary, William, Basem M., primary, Brammer, Jonathan E., primary, Smith, Sonali M., primary, Prica, Anca, primary, Zain, Jasmine M., primary, Tuscano, Joseph M., primary, Shah, Harsh, primary, Mehta-Shah, Neha, primary, Geethakumari, Praveen Ramakrishnan, primary, Wang, Ben X., primary, Zantinge, Stephanie, primary, Wang, Lisa, primary, Zhang, Ling, primary, Boutrin, Anmarie, primary, Zhao, Weiguang, primary, Cheng, Lily, primary, Standifer, Nathan, primary, Hewitt, Lisa, primary, Enowtambong, Enowmpey, primary, Shao, Weiping, primary, Sharma, Shringi, primary, Carlesso, Gianluca, primary, Moscow, Jeffrey A., primary, and Siu, Lillian L., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Data1 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Author

Chavez, Julio C., primary, Foss, Francine M., primary, William, Basem M., primary, Brammer, Jonathan E., primary, Smith, Sonali M., primary, Prica, Anca, primary, Zain, Jasmine M., primary, Tuscano, Joseph M., primary, Shah, Harsh, primary, Mehta-Shah, Neha, primary, Geethakumari, Praveen Ramakrishnan, primary, Wang, Ben X., primary, Zantinge, Stephanie, primary, Wang, Lisa, primary, Zhang, Ling, primary, Boutrin, Anmarie, primary, Zhao, Weiguang, primary, Cheng, Lily, primary, Standifer, Nathan, primary, Hewitt, Lisa, primary, Enowtambong, Enowmpey, primary, Shao, Weiping, primary, Sharma, Shringi, primary, Carlesso, Gianluca, primary, Moscow, Jeffrey A., primary, and Siu, Lillian L., primary

Published
2023
Full Text
View/download PDF

29. Suppl Fig 3 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Author

Chavez, Julio C., primary, Foss, Francine M., primary, William, Basem M., primary, Brammer, Jonathan E., primary, Smith, Sonali M., primary, Prica, Anca, primary, Zain, Jasmine M., primary, Tuscano, Joseph M., primary, Shah, Harsh, primary, Mehta-Shah, Neha, primary, Geethakumari, Praveen Ramakrishnan, primary, Wang, Ben X., primary, Zantinge, Stephanie, primary, Wang, Lisa, primary, Zhang, Ling, primary, Boutrin, Anmarie, primary, Zhao, Weiguang, primary, Cheng, Lily, primary, Standifer, Nathan, primary, Hewitt, Lisa, primary, Enowtambong, Enowmpey, primary, Shao, Weiping, primary, Sharma, Shringi, primary, Carlesso, Gianluca, primary, Moscow, Jeffrey A., primary, and Siu, Lillian L., primary

Published
2023
Full Text
View/download PDF

30. Suppl Fig 1 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Author

Chavez, Julio C., primary, Foss, Francine M., primary, William, Basem M., primary, Brammer, Jonathan E., primary, Smith, Sonali M., primary, Prica, Anca, primary, Zain, Jasmine M., primary, Tuscano, Joseph M., primary, Shah, Harsh, primary, Mehta-Shah, Neha, primary, Geethakumari, Praveen Ramakrishnan, primary, Wang, Ben X., primary, Zantinge, Stephanie, primary, Wang, Lisa, primary, Zhang, Ling, primary, Boutrin, Anmarie, primary, Zhao, Weiguang, primary, Cheng, Lily, primary, Standifer, Nathan, primary, Hewitt, Lisa, primary, Enowtambong, Enowmpey, primary, Shao, Weiping, primary, Sharma, Shringi, primary, Carlesso, Gianluca, primary, Moscow, Jeffrey A., primary, and Siu, Lillian L., primary

Published
2023
Full Text
View/download PDF

32. Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines

Author

Thavendiranathan, Paaladinesh, primary, Houbois, Christian, additional, Marwick, Thomas H, additional, Kei, Tiffanie, additional, Saha, Sudipta, additional, Runeckles, Kyle, additional, Huang, Flora, additional, Shalmon, Tamar, additional, Thorpe, Kevin E, additional, Pezo, Rossanna C, additional, Prica, Anca, additional, Maze, Dawn, additional, Abdel-Qadir, Husam, additional, Connelly, Kim, additional, Chan, Joyce, additional, Billia, Filio, additional, Power, Coleen, additional, Hanneman, Kate, additional, Wintersperger, Bernd J, additional, Brezden-Masley, Christine, additional, and Amir, Eitan, additional

Published
2023
Full Text
View/download PDF

33. Data from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Author

Chavez, Julio C., primary, Foss, Francine M., primary, William, Basem M., primary, Brammer, Jonathan E., primary, Smith, Sonali M., primary, Prica, Anca, primary, Zain, Jasmine M., primary, Tuscano, Joseph M., primary, Shah, Harsh, primary, Mehta-Shah, Neha, primary, Geethakumari, Praveen Ramakrishnan, primary, Wang, Ben X., primary, Zantinge, Stephanie, primary, Wang, Lisa, primary, Zhang, Ling, primary, Boutrin, Anmarie, primary, Zhao, Weiguang, primary, Cheng, Lily, primary, Standifer, Nathan, primary, Hewitt, Lisa, primary, Enowtambong, Enowmpey, primary, Shao, Weiping, primary, Sharma, Shringi, primary, Carlesso, Gianluca, primary, Moscow, Jeffrey A., primary, and Siu, Lillian L., primary

Published
2023
Full Text
View/download PDF

36. Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Author

Chavez, Julio C., primary, Foss, Francine M., additional, William, Basem M., additional, Brammer, Jonathan E., additional, Smith, Sonali M., additional, Prica, Anca, additional, Zain, Jasmine M., additional, Tuscano, Joseph M., additional, Shah, Harsh, additional, Mehta-Shah, Neha, additional, Geethakumari, Praveen Ramakrishnan, additional, Wang, Ben X., additional, Zantinge, Stephanie, additional, Wang, Lisa, additional, Zhang, Ling, additional, Boutrin, Anmarie, additional, Zhao, Weiguang, additional, Cheng, Lily, additional, Standifer, Nathan, additional, Hewitt, Lisa, additional, Enowtambong, Enowmpey, additional, Shao, Weiping, additional, Sharma, Shringi, additional, Carlesso, Gianluca, additional, Moscow, Jeffrey A., additional, and Siu, Lillian L., additional

Published
2023
Full Text
View/download PDF

39. Impact of Geriatric Assessment and Management on Quality of Life, Unplanned Hospitalizations, Toxicity, and Survival for Older Adults With Cancer: The Randomized 5C Trial

Author

Puts, Martine, primary, Alqurini, Naser, additional, Strohschein, Fay, additional, Koneru, Rama, additional, Szumacher, Ewa, additional, Mariano, Caroline, additional, Monette, Johanne, additional, Hsu, Tina, additional, Brennenstuhl, Sarah, additional, McLean, Bianca, additional, Wills, Aria, additional, Berger, Arielle, additional, Amir, Eitan, additional, Romanovsky, Lindy, additional, Li, Anson, additional, Mehta, Rajin, additional, Krzyzanowska, Monika, additional, Elser, Christine, additional, Jang, Raymond, additional, Prica, Anca, additional, Wan-Chow-Wah, Doreen, additional, Pitters, Eric, additional, Emmenegger, Urban, additional, Menjak, Ines B., additional, Bergman, Simon, additional, Lemonde, Manon, additional, Breunis, Henriette, additional, Béland, Francois, additional, and Alibhai, Shabbir M.H., additional

Published
2023
Full Text
View/download PDF

41. International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Author

Binkley, Michael S., primary, Flerlage, Jamie E., additional, Borchmann, Peter, additional, Fuchs, Michael, additional, Hartmann, Sylvia, additional, Eich, Hans Theodor, additional, Savage, Kerry J., additional, Lo, Andrea C., additional, Skinnider, Brian, additional, Akhtar, Saad, additional, Rauf, M. Shahzad, additional, Maghfoor, Irfan, additional, Pinnix, Chelsea, additional, Steiner, Raphael, additional, Milgrom, Sarah A., additional, Vega, Francisco, additional, Alomari, Mohammed, additional, Yang, Xiao-Yin, additional, Collins, Graham, additional, Advani, Ranjana H., additional, Metzger, Monika, additional, Dickinson, Michael, additional, Wirth, Andrew, additional, Tsang, Richard, additional, Prica, Anca, additional, Major, Ajay, additional, Smith, Sonali, additional, Hendrickson, Peter G., additional, Kelsey, Chris R., additional, Hopkins, David, additional, McKay, Pam, additional, Ng, Andrea, additional, Koenig, Julie, additional, Constine, Louis S., additional, Casulo, Carla, additional, Sakthivel, Gukan, additional, Baron, Jonathan, additional, Plastaras, John P., additional, Roberts, Kenneth B., additional, Gao, Sarah, additional, Al Kendi, Jalila, additional, Al Rahbi, Nasser, additional, Balogh, Alex, additional, Levis, Mario, additional, Ricardi, Umberto, additional, Sridhar, Akshay, additional, Torka, Pallawi, additional, Specht, Lena, additional, De Silva, Ravindu, additional, Shah, Nimish, additional, Pickard, Keir, additional, Osborne, Wendy, additional, Blazin, Lindsay J., additional, Henry, Michael, additional, Chang, Isabela, additional, Smith, Christine M., additional, Halperin, Daniel, additional, Miall, Fiona, additional, Brady, Jessica, additional, Mikhaeel, George, additional, Brennan, Bernadette, additional, Penn, Anthony, additional, Senchenko, Mariia Anatolevna, additional, Volchkov, Egor Vasilevich, additional, Reeves, Marie, additional, Hoppe, Bradford S., additional, Terezakis, Stephanie, additional, Talaulikar, Dipti, additional, Della Pepa, Roberta, additional, Picardi, Marco, additional, Kirova, Youlia, additional, Fergusson, Paige, additional, Northend, Michael, additional, Hawkes, Eliza, additional, Lee, Denise, additional, Wong Doo, Nicole, additional, Barraclough, Allison, additional, Opat, Stephen, additional, Cheah, Chan, additional, Salvaris, Ross, additional, Ku, Matthew, additional, Hamad, Nada, additional, Mutsando, Howard, additional, Tedjaseputra, Aditya, additional, Gilbertson, Michael, additional, Marconi, Tamara, additional, Viiala, Nicholas, additional, Palese, Monica, additional, Shankar, Ananth, additional, Maurer, Matthew J., additional, Natkunam, Yasodha, additional, Kelly, Kara M., additional, Eichenauer, Dennis A., additional, and Hoppe, Richard T., additional

Published
2023
Full Text
View/download PDF

43. The association between nutritional risk index and ICU outcomes across hematologic malignancy patients with acute respiratory failure

Author

Kundu, Riddhi, primary, Seeger, Rena, additional, Elfassy, Michael D., additional, Rozenberg, Dmitry, additional, Ahluwalia, Nanki, additional, Detsky, Michael E., additional, Ferreyro, Bruno L., additional, Mehta, Sangeeta, additional, Law, Arjun Datt, additional, Minden, Mark, additional, Prica, Anca, additional, Sklar, Michael, additional, and Munshi, Laveena, additional

Published
2022
Full Text
View/download PDF

45. Chromosome 1q Abnormalities Are Not an Independent Predictor of Survival in Multiple Myeloma

Author

Patel, Ashish, primary, Smith, Adam C., additional, Masih-Khan, Esther, additional, Samuel, Peace, additional, Lajkosz, Katherine, additional, Bhella, Sita, additional, Chen, Christine I., additional, Prica, Anca, additional, Reece, Donna E., additional, Stewart, A. Keith, additional, Tiedemann, Rodger E, additional, Trudel, Suzanne, additional, Yang, Chloe, additional, and Kukreti, Vishal, additional

Published
2022
Full Text
View/download PDF

46. A Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects with Relapsed/Refractory Peripheral T-Cell Lymphoma

Author

Shortt, Jake, primary, Poligone, Brian, additional, Ribrag, Vincent, additional, Zinzani, Pier Luigi, additional, El-Sharkawi, Dima, additional, Walewski, Jan, additional, Prica, Anca, additional, Wilson, Laksmi, additional, Souza, Sonia, additional, Keer, Harold N., additional, Taylor, Jason A., additional, and Marchi, Enrica, additional

Published
2022
Full Text
View/download PDF

48. Frailty in Patients Undergoing Chimeric Antigen Receptor T-Cell (CAR T) Therapy at Princess Margaret Cancer Centre: A Prospective Pilot Study

Author

Prica, Anca, primary, Coley, Tiana, additional, Aitken, Rachel, additional, Vijenthira, Abi, additional, Maganti, Manjula, additional, Mayo, Samantha J, additional, Chen, Christine I., additional, Kuruvilla, John, additional, Crump, Michael, additional, Bhella, Sita, additional, Kridel, Robert, additional, Kukreti, Vishal, additional, Yang, Chloe, additional, and Alibhai, Shabbir, additional

Published
2022
Full Text
View/download PDF

49. The Impact of Drug Interactions on Outcomes in Ibrutinib-Treated Patients with Chronic Lymphocytic Leukemia in Routine Clinical Care: A Population-Based Cohort Study

Author

Hoang, Tuan, primary, Cheung, Matthew C., additional, Chan, Kelvin KW, additional, Lau, Cindy, additional, Liu, Ning, additional, Abdel-Qadir, Husam, additional, Juurlink, David, additional, Prica, Anca, additional, Thawer, Alia, additional, Vijenthira, Abi, additional, and Mozessohn, Lee, additional

Published
2022
Full Text
View/download PDF

50. Correlation Amongst Scoring of Various Frailty Tools in Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Author

Devasia, Anup Joseph, primary, Khan, Sahar, additional, Paul, Harminder K, additional, Larose, Frédéric, additional, Atenafu, Eshetu G., additional, Reece, Donna E., additional, Trudel, Suzanne, additional, Stewart, A. Keith, additional, Bhella, Sita, additional, Kukreti, Vishal, additional, Yang, Chloe, additional, Tiedemann, Rodger E, additional, Prica, Anca, additional, Monchis, Monica, additional, Leung, Eugene, additional, Jomah, Susan, additional, Mohamed, Zubaida, additional, and Chen, Christine, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results